US5089400A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polypeptides and process for the production thereof
Assignee: Novartis Corp
•
Filing: 1989-03-07
•
Granted: 1992-02-18
•
Expires: 2009-03-07
Abstract
Abstract Recombinant DNA molecules and hosts transformed with them are described which produce polypeptides displaying a human lymphoblastoid interferon activity. There are also provided processes for the preparation of said recombinant DNA molecules, said hosts, and said lymphoblastoid interferon-like polypeptides. The polypeptides of the invention are useful as immunomodulators, especially as antiviral, antitumor and anticancer agents.
Inventors
- 👤 Francois Meyer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 21:07
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; A; A61; A61P; A61P31/00; A61P31/12; A61P35/00; A61P35/02; C12N15/63; C12N15/70
Claims Analysis
Total Claims: 34
Claim 1
Independent Claim
109 words
A method for producing a polypeptide selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1, and LyIFN-α-2 which comprises: (a) preparing from HuLyIFN-mRNA a single-stranded complementary DNA and, if required, therefrom a double-stranded cDNA coding for any of said polypeptides; or (b) partially cleaving the chromosomal DNA of human lymphoblastoid cells and selecting DNA fragments which contain chromosomal LyIFN genes coding for any of said polypeptides; (c) introducing into a vector DNA the complementary DNA from step (a) or the DNA fragments which contain chromosomal LyIFN genes from step (b); (d) transforming a host cell with the vector from step (c); (e) culturing the transformed host; and (f) recovering said polypeptide.
Claim 2
Independent Claim
109 words
A method for producing a polypeptide selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1, and LyIFN-α-2 which comprises: (a) preparing from HuLyIFN-mRNA a single-stranded complementary DNA and, if required, therefrom a double-stranded cDNA coding for any of said polypeptides; or (b) partially cleaving the chromosomal DNA of human lymphoblastoid cells and selecting DNA fragments which contain chromosomal LyIFN genes coding for any of said polypeptides; (c) introducing into a vector DNA the complementary DNA from step (a) or the DNA fragments which contain chromosomal LyIFN genes from step (b); (d) transforming a host cell with the vector from step (c); (e) culturing the transformed host; and (f) recovering said polypeptide.
Claim 3
Dependent Claim
11 words
A method according to claim 1 wherein the interferon is LyIFN-α-1.
Claim 4
Dependent Claim
11 words
A method according to claim 1 wherein the interferon is LyIFN-α-2.
Claim 5
Dependent Claim
90 words
A DNA in substantially pure form containing a DNA sequence which codes for HLycIFN-1'b and consists of: ACATCCCAATGGCCCTGTCCTTTTCTTTACTGATGGCCGTGCTGGTGCTCAGCTACAAATCCATCTGT TCTCTGGGCTGTGATCTCCCTCAGACCCACAGCCTGGGTAATAGGAGGGCCTTGATACTCCTGGCACA AATGGGAAGAATCCCCCCTTTCTCCTGCCTGAAGGACAGACATGACTTTGGATTTCCCCAGGAGGACT TTGATGGCAACCAGTTCCAGAAGGCTCAAGCCATCTCTGTCCTCCATGAGATGATCCAGCACACCTTC AATCTCTTCAGCACAAAGGACTCATCTGCTACTTGGGAACAGAGCCTCCTAGAAAATTTTCCACTGA ACTTAACCAGCAGCTGAATGACCTGGAAGCCTGCGTGATACAGGAGGTTGGGGTGGAAGAGACTCCCC TGATGAATGTGGACTCCATCCTGGCTGTGAAGAAATACTTCCAAACAATCACTCTTTATCTGACAGAG AAGAAATACAGCCCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAAA AATTTTTCAAGAAAGATTAAGGAGGAAGGAATGAAACCTGTTTCAACATGCAAATGATCTGTATTGAC TAATACACCAGTCCACACTTCTATGACTTCTGCCATTTCAAAGACTCATTTCTCCTATAACCACCGCA TGAGTTCAATCAAAATTTTCAGATCTTTTCAGGACTGTAAGGAAACATCATGTTTACCTGTGCAGGCA CTAGTCCTTTACAGATGACCATGCTGATAGATCTAATTATCTATCTATTGAAATATTTATTTATTTAT TAGATTTAAATTATTTTTGTCCATGTAATATTATGTGTACTTTTACATTGTGTTATATCAAAATATGT TATTTATATTTAGTCAATATATTATTTTCTTTTTATTAATTTTTACTATTAAAACTTCTTATATTATT TGTTTATTG, HLycIFN-5 1 and consists of: ATCTGAACCAGCTCAGCAGCATCCACAACATCTACAATGGCCTTGACTTTTTATTTACTGGTGGCCC TAGTGGTGCTCAGCTACAAGTCATTCAGCTCTCTGGGCTGCGATCTGCCTCAGACTCACAGCCTGGG TAACAGGAGGGCCTTGATACTCCTGGCACAAATGCGAAGAATCTCTCCTTTCTCCTGCCTGAAGGAC AGACATGACTTTGAATTCCCCCAGGAGGAGTTTGATGATAAACAGTTCCAGAAGGCTCAAGCCATCT CTGTCCTCCATGAGATGATCCAGCAGACCTTCAACCTCTTCAGCACAAAGGACTCACCTGCTGCTTT GGATGAGACCCTTCTAGATGAATTCTACACTGAACTTGACCAGCAGCTGAATGACCTGCAG TCCTGTGTGATGCAGGAAGTGGGGGTGATAGAGTCTCCCCTGATGTACGAGGACTCCTCTCTGGCTG TGAGGAAATACTTCCAAAGAATCACTCTATATCTGACAGAGAAGAAATACAGCTCTTGTGCCTGGGA GGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAATCAACTTGCAAAAAAGATTGAAGAGT AAGGAATGAGACCTGGTACAACACGGAAATGATTCTTATAGACTAATACAGCAGCTCACACTCTGAC AAGTTGTGCTCTTTCAAAGACCCTTGTTTCTGCCAAAACCATGCTATGTTTTGAATCAAATGTGTCA ATGTTTTTCAGGAGTGTTAAGCAACATCCTGTTCAGCTGTATGGGCACTAGTCCCTTACAGATGACC ATGCTGATGGATCTATTCATCTATTTATTTAAATCTTTATTTAGTTAACTATCTATAGGGCTTAAAT TATGTTTGTTCATATTATATTATGTGAACTTTTATATGATGAATTGTGTAACAAAAACATGTCTTTT ATATTAATTATTTTGCCTTCTTTATTAAATTTTTACTATAG for LyIFN-α-1 and consists of: GAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTAATGTGTGATCTGCCTCA GACCCACAGCCTGGGTAATAGGAGGGCCTTGATACTCTCGGCACACATGGAAGAATCCCCCCTTTC TCCTGCCTGAAGGACAGACATGACTTTGGATTTCCCCACGAGGAGTTTGATGGCAACCAGTTCCAGA AGGCTCAAGCCATCTCTGTCCTCCATCAGATGATCCAGCAGACCTTCAATCTCTCTAGCACAAAGG ACTCATCTGCTACTTGGGAACAGAGCCTCCTAGAAAAATTTTCCACTGAACTTAACCAGCAGCTGAA TGACCTGGAAGCCTGCGTGATACAGGAGGTTGGGGTGGAAGAGACTCCCCTGATGAATGTGGACTCC ATCCTGGCTGTGAAGAAATACCCTCAAAGAATCACTCTTTATCTGACAGAGAAGAAATACAGCCCTT GTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGATCCCTCTCTTTATCAAAAATTTTTCAAGAAAG ATTAAGGAGGAAGGAATGAAACCTGTTTCAACATGGAAATGATCTGTATTGACTAATACACCAGTCC AATTTTCAGATCTTTTCAGGAGTGTAAGGAAACATCATGTTTACCTGTGCAGGCACTATGCCTTTAC AGATGACCATGCTGATAGATCTAATTATCTATCTATTGAAATATTTATTTATTTATTAGATTTAAAT TATTTTTGTCGATGTAATATTATGTGTACTCTTACATTGTGTTATATCAAAATATGTTATTTATATT TAGTCAATATATTATTTTTCTTTTATTAATTTTTACTATTAAAACTCTTTATATTATTTGTTTATTC or for LyIFN-α-2 and consists of: GAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGCAAGAGTAATGTGTGATCTGCCTC AGACTCACAGCCTGGGTAACAGGAGGGCCTTGATACTCCTGGCACAAATAAGAATCTCTCCTT TCTCCTGCCTGAAGGACAGACATCACTTTGAATTCCCCCAGGAGGAGTTTGATGATAAACAGTCCC AGAAGGCTCAAGCCATCTCTGTCCTCCATGAGATGATCCAGCAGACCTTCAACCTCTTCAGCACAA AGGACTCATCTGCTGCTTTGGATGAGACCCTTCTAGATGAATTCTACATCGAACTTGACCAGCAGC TGAATGACCTGGAGGTCTCTGTGATGCAGGAAGTGGGGGTGATAGAGTCTCCCCTGATGTACGAGG ACTCCATCCTGGCTGTGAGGAAATACTTCCAAAGAATCACTCTATATCTGACAGAGAAGAAATACA GCTCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAATCAACTTGC AAAAAAGATTGAAGAGTAAGGAATGAGACCTCGTACAACACGGAAATGATTCTTATAGACTAATAC AGCAGTCTACACTTCGACAAGTTGTGCTCTTTCAAAGACCCTTGTTTCTGCCAAAACCATGCTATG TTTTGAATCAAATGTGTCAAGTGTTTTCAGGAGTGTTAAGCAACATCCTGTTCAGCTGTATGGGCA CTAGTCCCTTACAGATGACCATCTTGATGGATCTATTCATCTATTTATTTAAATCTTTATTTAGTT AACTATCTATAGGGCTTAAATTAGTTTTGTTCATATTATATTATGTGAACTTTTACATTCTGAATT GTGTAACAAAAACATGTTCTTTATATTTATTATTTTGCTCTGTTTATTAAATTTTTACTATAG
Claim 6
Dependent Claim
90 words
A DNA in substantially pure form containing a DNA sequence which codes for HLycIFN-1'b and consists of: ACATCCCAATGGCCCTGTCCTTTTCTTTACTGATGGCCGTGCTGGTGCTCAGCTACAAATCCATCTGT TCTCTGGGCTGTGATCTCCCTCAGACCCACAGCCTGGGTAATAGGAGGGCCTTGATACTCCTGGCACA AATGGGAAGAATCCCCCCTTTCTCCTGCCTGAAGGACAGACATGACTTTGGATTTCCCCAGGAGGACT TTGATGGCAACCAGTTCCAGAAGGCTCAAGCCATCTCTGTCCTCCATGAGATGATCCAGCACACCTTC AATCTCTTCAGCACAAAGGACTCATCTGCTACTTGGGAACAGAGCCTCCTAGAAAATTTTCCACTGA ACTTAACCAGCAGCTGAATGACCTGGAAGCCTGCGTGATACAGGAGGTTGGGGTGGAAGAGACTCCCC TGATGAATGTGGACTCCATCCTGGCTGTGAAGAAATACTTCCAAACAATCACTCTTTATCTGACAGAG AAGAAATACAGCCCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAAA AATTTTTCAAGAAAGATTAAGGAGGAAGGAATGAAACCTGTTTCAACATGCAAATGATCTGTATTGAC TAATACACCAGTCCACACTTCTATGACTTCTGCCATTTCAAAGACTCATTTCTCCTATAACCACCGCA TGAGTTCAATCAAAATTTTCAGATCTTTTCAGGACTGTAAGGAAACATCATGTTTACCTGTGCAGGCA CTAGTCCTTTACAGATGACCATGCTGATAGATCTAATTATCTATCTATTGAAATATTTATTTATTTAT TAGATTTAAATTATTTTTGTCCATGTAATATTATGTGTACTTTTACATTGTGTTATATCAAAATATGT TATTTATATTTAGTCAATATATTATTTTCTTTTTATTAATTTTTACTATTAAAACTTCTTATATTATT TGTTTATTG, HLycIFN-5 1 and consists of: ATCTGAACCAGCTCAGCAGCATCCACAACATCTACAATGGCCTTGACTTTTTATTTACTGGTGGCCC TAGTGGTGCTCAGCTACAAGTCATTCAGCTCTCTGGGCTGCGATCTGCCTCAGACTCACAGCCTGGG TAACAGGAGGGCCTTGATACTCCTGGCACAAATGCGAAGAATCTCTCCTTTCTCCTGCCTGAAGGAC AGACATGACTTTGAATTCCCCCAGGAGGAGTTTGATGATAAACAGTTCCAGAAGGCTCAAGCCATCT CTGTCCTCCATGAGATGATCCAGCAGACCTTCAACCTCTTCAGCACAAAGGACTCACCTGCTGCTTT GGATGAGACCCTTCTAGATGAATTCTACACTGAACTTGACCAGCAGCTGAATGACCTGCAG TCCTGTGTGATGCAGGAAGTGGGGGTGATAGAGTCTCCCCTGATGTACGAGGACTCCTCTCTGGCTG TGAGGAAATACTTCCAAAGAATCACTCTATATCTGACAGAGAAGAAATACAGCTCTTGTGCCTGGGA GGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAATCAACTTGCAAAAAAGATTGAAGAGT AAGGAATGAGACCTGGTACAACACGGAAATGATTCTTATAGACTAATACAGCAGCTCACACTCTGAC AAGTTGTGCTCTTTCAAAGACCCTTGTTTCTGCCAAAACCATGCTATGTTTTGAATCAAATGTGTCA ATGTTTTTCAGGAGTGTTAAGCAACATCCTGTTCAGCTGTATGGGCACTAGTCCCTTACAGATGACC ATGCTGATGGATCTATTCATCTATTTATTTAAATCTTTATTTAGTTAACTATCTATAGGGCTTAAAT TATGTTTGTTCATATTATATTATGTGAACTTTTATATGATGAATTGTGTAACAAAAACATGTCTTTT ATATTAATTATTTTGCCTTCTTTATTAAATTTTTACTATAG for LyIFN-α-1 and consists of: GAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTAATGTGTGATCTGCCTCA GACCCACAGCCTGGGTAATAGGAGGGCCTTGATACTCTCGGCACACATGGAAGAATCCCCCCTTTC TCCTGCCTGAAGGACAGACATGACTTTGGATTTCCCCACGAGGAGTTTGATGGCAACCAGTTCCAGA AGGCTCAAGCCATCTCTGTCCTCCATCAGATGATCCAGCAGACCTTCAATCTCTCTAGCACAAAGG ACTCATCTGCTACTTGGGAACAGAGCCTCCTAGAAAAATTTTCCACTGAACTTAACCAGCAGCTGAA TGACCTGGAAGCCTGCGTGATACAGGAGGTTGGGGTGGAAGAGACTCCCCTGATGAATGTGGACTCC ATCCTGGCTGTGAAGAAATACCCTCAAAGAATCACTCTTTATCTGACAGAGAAGAAATACAGCCCTT GTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGATCCCTCTCTTTATCAAAAATTTTTCAAGAAAG ATTAAGGAGGAAGGAATGAAACCTGTTTCAACATGGAAATGATCTGTATTGACTAATACACCAGTCC AATTTTCAGATCTTTTCAGGAGTGTAAGGAAACATCATGTTTACCTGTGCAGGCACTATGCCTTTAC AGATGACCATGCTGATAGATCTAATTATCTATCTATTGAAATATTTATTTATTTATTAGATTTAAAT TATTTTTGTCGATGTAATATTATGTGTACTCTTACATTGTGTTATATCAAAATATGTTATTTATATT TAGTCAATATATTATTTTTCTTTTATTAATTTTTACTATTAAAACTCTTTATATTATTTGTTTATTC or for LyIFN-α-2 and consists of: GAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGCAAGAGTAATGTGTGATCTGCCTC AGACTCACAGCCTGGGTAACAGGAGGGCCTTGATACTCCTGGCACAAATAAGAATCTCTCCTT TCTCCTGCCTGAAGGACAGACATCACTTTGAATTCCCCCAGGAGGAGTTTGATGATAAACAGTCCC AGAAGGCTCAAGCCATCTCTGTCCTCCATGAGATGATCCAGCAGACCTTCAACCTCTTCAGCACAA AGGACTCATCTGCTGCTTTGGATGAGACCCTTCTAGATGAATTCTACATCGAACTTGACCAGCAGC TGAATGACCTGGAGGTCTCTGTGATGCAGGAAGTGGGGGTGATAGAGTCTCCCCTGATGTACGAGG ACTCCATCCTGGCTGTGAGGAAATACTTCCAAAGAATCACTCTATATCTGACAGAGAAGAAATACA GCTCTTGTGCCTGGGAGGTTGTCAGAGCAGAAATCATGAGATCCTTCTCTTTATCAATCAACTTGC AAAAAAGATTGAAGAGTAAGGAATGAGACCTCGTACAACACGGAAATGATTCTTATAGACTAATAC AGCAGTCTACACTTCGACAAGTTGTGCTCTTTCAAAGACCCTTGTTTCTGCCAAAACCATGCTATG TTTTGAATCAAATGTGTCAAGTGTTTTCAGGAGTGTTAAGCAACATCCTGTTCAGCTGTATGGGCA CTAGTCCCTTACAGATGACCATCTTGATGGATCTATTCATCTATTTATTTAAATCTTTATTTAGTT AACTATCTATAGGGCTTAAATTAGTTTTGTTCATATTATATTATGTGAACTTTTACATTCTGAATT GTGTAACAAAAACATGTTCTTTATATTTATTATTTTGCTCTGTTTATTAAATTTTTACTATAG
Claim 7
Dependent Claim
13 words
A DNA according to claim 4 wherein the DNA sequence code for HLycIFN-1'b.
Claim 8
Dependent Claim
15 words
A DNA according to claim 4 wherein the DNA sequence code for HLycIFN-5 1 .
Claim 9
Dependent Claim
13 words
A DNA according to claim 4 wherein the DNA sequence code for LyIFN-α-1.
Claim 10
Dependent Claim
13 words
A DNA according to claim 4 wherein the DNA seuqence code for LyIFN-α-2.
Claim 11
Dependent Claim
20 words
A recombinant DNA containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1 or LyIFN-α-2.
Claim 12
Dependent Claim
20 words
A recombinant DNA containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1 or LyIFN-α-2.
Claim 13
Dependent Claim
9 words
The recombinant DNA CG-pBR 322/HLycIFN-1'b, according to claim 9.
Claim 14
Dependent Claim
11 words
The recombinant DNA CG-pBR 322/HLycIFN-5 1 , according to claim 9.
Claim 15
Dependent Claim
16 words
A recombinant DNA according to claim 9 containing the expression control sequence of the β-lactamase gene.
Claim 16
Dependent Claim
39 words
A host cell transformed with at least one recombinant DNA containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1 and LyIFN-α-2 and mutants of said host cell containing any of said DNA sequences.
Claim 17
Dependent Claim
39 words
A host cell transformed with at least one recombinant DNA containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1 and LyIFN-α-2 and mutants of said host cell containing any of said DNA sequences.
Claim 18
Dependent Claim
27 words
A transformed host cell according to claim 13 selected from a bacillus, a yeast, a fungi, an animal or plant host cell or a human tissue cell.
Claim 19
Dependent Claim
12 words
A transformed E. coli strain according to claim 13 and mutants thereof.
Claim 20
Dependent Claim
18 words
The transformed host E. coli HB 101 CG-pBR 322/HLycIFN-1'b (NRRL B-12530), and mutants thereof, according to claim 13.
Claim 21
Dependent Claim
19 words
The transformed host E. coli HB 101 CG-pBR 322/HLycIFN-5 1 (NRRL B-12531) and mutants thereof, according to claim 13.
Claim 22
Independent Claim
71 words
A method for the preparation of DNA containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1, or LyIFN-α-2 which comprises: (a) preparing from HyLyIFN-mRNA a single-stranded complementary DNA and, therefrom a double-stranded cDNA coding for any of said polypeptides; or (b) partially cleaving the chromosomal DNA of human lymphoblastoid cells and selecting DNA fragments which contain chromosomal LyIFN genes coding for any of said polypeptides.
Claim 23
Independent Claim
71 words
A method for the preparation of DNA containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1, or LyIFN-α-2 which comprises: (a) preparing from HyLyIFN-mRNA a single-stranded complementary DNA and, therefrom a double-stranded cDNA coding for any of said polypeptides; or (b) partially cleaving the chromosomal DNA of human lymphoblastoid cells and selecting DNA fragments which contain chromosomal LyIFN genes coding for any of said polypeptides.
Claim 24
Dependent Claim
28 words
A method according to claim 18 comprising the additional step of introducing into a vector DNA the complementary DNA from step (a) or the fragments from step (b).
Claim 25
Dependent Claim
11 words
A method according to claim 19 wherein the interferon is LyIFN-α-1.
Claim 26
Dependent Claim
11 words
A method according to claim 19 wherein the interferon is LyIFN-α-2.
Claim 27
Dependent Claim
11 words
A method according to claim 18 wherein the interferon is LyIFN-α-1.
Claim 28
Dependent Claim
11 words
A method according to claim 18 wherein the interferon is LyIFN-α-2.
Claim 29
Independent Claim
116 words
A method for producing a transformed host cell containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1 and LyIFN-α-2 which comprises: (a) preparing from HuLyIFN-mRNA a single-stranded complementary DNA and, if required, therefrom a double-stranded complementary DNA and, therefrom a double-stranded cDNA coding for any of said polypeptides; or (b) partially cleaving the chromosomal DNA of human lympholastoid cells and selecting DNA fragments which contain chromosomal LyIFN genes coding for any of said polypeptides; (c) introducing into a vector DNA the complementary DNA from step (a) or the DNA fragments which contain chromosomal LyIFN genes from step (b); and (d) transforming a host cell with the vector from step (c).
Claim 30
Independent Claim
116 words
A method for producing a transformed host cell containing a DNA sequence coding for an interferon selected from HLycIFN-1'b, HLycIFN-5 1 , LyIFN-α-1 and LyIFN-α-2 which comprises: (a) preparing from HuLyIFN-mRNA a single-stranded complementary DNA and, if required, therefrom a double-stranded complementary DNA and, therefrom a double-stranded cDNA coding for any of said polypeptides; or (b) partially cleaving the chromosomal DNA of human lympholastoid cells and selecting DNA fragments which contain chromosomal LyIFN genes coding for any of said polypeptides; (c) introducing into a vector DNA the complementary DNA from step (a) or the DNA fragments which contain chromosomal LyIFN genes from step (b); and (d) transforming a host cell with the vector from step (c).
Claim 31
Dependent Claim
11 words
A method according to claim 24 wherein the interferon is LyIFN-α-1.
Claim 32
Dependent Claim
11 words
A method according to claim 24 wherein the interferon is LyIFN-α-2.
Claim 33
Dependent Claim
751 words
A DNA in substantially pure form which, on expression, codes for a polypeptide selected from the group consisting of HLycIFN-1'b having the sequence MET ALA LEU SER PHE SER LEU LEU MET ALA VAL LEU VAL LEU SER TYR LYS SER ILE CYS SER LEU GLY CYS ASP LEU PRO GLN THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET GLY ARG ILE PRO PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY PHE PRO GLN GLU GLU PHE ASP GLY ASN GLN PHE GLN LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET LLE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA THR TRP GLU GLN SER LEU LEU GLU LYS PHE SER THR GLU LEU ASN GLN GLN LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLU VAL GLY VAL GLU GLU THR PRO LEU MET ASN VAL ASP SER ILE LEU ALA VAL LYS LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER PRO CYS ALA TRP GLU VAL VAL ARG ALA CLU ILE MET ARG SER PHE SER LEU SER LYS ILE PHE GLN GLU ARG LEU ARG ARG LYS GLU, HLycIFN-5 1 having the sequence MET ALA LEU THR PHE TYR LEU LEU VAL ALA LEU VAL VAL LEU SER TYR LYS SER PHE SER SER LEU GLY CYS ASP LEU PRO GLY THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLY MET ARG ARG ILE SER PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLU PHE PRO GLN GLU GLU PHE ASP ASP LYN GLN PHE GLN LYS ALS GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA ALA LEU ASP GLU THR LEU LEU ASP GLU PHE TYR ILE GLU LEU ASP GLN GLN LEU ASN ASP LEU GLU SER CYS VAL MET GLN GLU VAL GLY VAL ILE GLU SER PRO LEU MET TYR GLU ASP SER ILE LEU ALA VAL ARG LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER SER CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER ILE ASN LEU GLN LYS ARG LEU LYS SER LYS GLU, an interferon having the sequence MET CYS ASP LEU PRO GLN THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET GLY ARG ILE PRO PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY PHE PRO GLN GLU GLU PHE ASP GLY ASN GLN PHE GLY LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA THR TRP GLU GLN SER LEU LEU GLU LYS PHE SER THR GLU LEU ASN GLN GLN LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLU VAL GLY VAL GLU GLU THR PRO LEU MET ASN VAL ASP SER ILE LEU ALA VAL LYS LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER PRO CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER LYS ILE PHE GLN GLU ARG LEU ARG ARG LYS GLU, and an interferon having the sequence MET CYS ASP LEU PRO GLN THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET ARG ARG ILE SER PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLU PHE PRO GLN GLU GLU PHE ASP ASP LYS GLN PHE GLN LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA ALA LEU ASP GLU THR LEU LEU ASP GLU PHE TYR ILE GLU LEU ASP GLN GLN LEU ASN ASP LEU GLU SER CYS VAL MET GLN GLU VAL VLY VAL ILE GLU SER PRO LEU MET TYR GLU ASP SER ILE LEU ALA VAL ARG LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER SER CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER ILE ASN LEU GLN LYS ARG LEU LYS SER LYS GLU.
Claim 34
Dependent Claim
751 words
A DNA in substantially pure form which, on expression, codes for a polypeptide selected from the group consisting of HLycIFN-1'b having the sequence MET ALA LEU SER PHE SER LEU LEU MET ALA VAL LEU VAL LEU SER TYR LYS SER ILE CYS SER LEU GLY CYS ASP LEU PRO GLN THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET GLY ARG ILE PRO PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY PHE PRO GLN GLU GLU PHE ASP GLY ASN GLN PHE GLN LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET LLE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA THR TRP GLU GLN SER LEU LEU GLU LYS PHE SER THR GLU LEU ASN GLN GLN LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLU VAL GLY VAL GLU GLU THR PRO LEU MET ASN VAL ASP SER ILE LEU ALA VAL LYS LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER PRO CYS ALA TRP GLU VAL VAL ARG ALA CLU ILE MET ARG SER PHE SER LEU SER LYS ILE PHE GLN GLU ARG LEU ARG ARG LYS GLU, HLycIFN-5 1 having the sequence MET ALA LEU THR PHE TYR LEU LEU VAL ALA LEU VAL VAL LEU SER TYR LYS SER PHE SER SER LEU GLY CYS ASP LEU PRO GLY THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLY MET ARG ARG ILE SER PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLU PHE PRO GLN GLU GLU PHE ASP ASP LYN GLN PHE GLN LYS ALS GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA ALA LEU ASP GLU THR LEU LEU ASP GLU PHE TYR ILE GLU LEU ASP GLN GLN LEU ASN ASP LEU GLU SER CYS VAL MET GLN GLU VAL GLY VAL ILE GLU SER PRO LEU MET TYR GLU ASP SER ILE LEU ALA VAL ARG LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER SER CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER ILE ASN LEU GLN LYS ARG LEU LYS SER LYS GLU, an interferon having the sequence MET CYS ASP LEU PRO GLN THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET GLY ARG ILE PRO PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY PHE PRO GLN GLU GLU PHE ASP GLY ASN GLN PHE GLY LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA THR TRP GLU GLN SER LEU LEU GLU LYS PHE SER THR GLU LEU ASN GLN GLN LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLU VAL GLY VAL GLU GLU THR PRO LEU MET ASN VAL ASP SER ILE LEU ALA VAL LYS LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER PRO CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER LYS ILE PHE GLN GLU ARG LEU ARG ARG LYS GLU, and an interferon having the sequence MET CYS ASP LEU PRO GLN THR HIS SER LEU GLY ASN ARG ARG ALA LEU ILE LEU LEU ALA GLN MET ARG ARG ILE SER PRO PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLU PHE PRO GLN GLU GLU PHE ASP ASP LYS GLN PHE GLN LYS ALA GLN ALA ILE SER VAL LEU HIS GLU MET ILE GLN GLN THR PHE ASN LEU PHE SER THR LYS ASP SER SER ALA ALA LEU ASP GLU THR LEU LEU ASP GLU PHE TYR ILE GLU LEU ASP GLN GLN LEU ASN ASP LEU GLU SER CYS VAL MET GLN GLU VAL VLY VAL ILE GLU SER PRO LEU MET TYR GLU ASP SER ILE LEU ALA VAL ARG LYS TYR PHE GLN ARG ILE THR LEU TYR LEU THR GLU LYS LYS TYR SER SER CYS ALA TRP GLU VAL VAL ARG ALA GLU ILE MET ARG SER PHE SER LEU SER ILE ASN LEU GLN LYS ARG LEU LYS SER LYS GLU.
References Cited (Backward Citations)
EP0041313A2
Cited
EP0051873A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-02-17 | 1995-08-19 | 1996-02-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-02-17 | 1999-08-19 | 2000-02-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-02-17 | 2003-08-19 | 2004-02-18 | $7700.00 | Window Closed / Lapsed |